FDA has accepted for review a supplemental Biologics License Application for Keytruda, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment for metastatic squamous non-small cell lung cancer, regardless of PD-L1 expression.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
